Compare Allstate Corp (ALL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs Incyte Corporation — how do they compare? Allstate Corp trades at $261 (market cap $66.31B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Allstate Corp is far larger — about 2.7× Incyte Corporation's market cap, and Allstate Corp pays a 1.65% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ALL | INCY | |
|---|---|---|
Market Cap | $66.31B | $24.54B |
Sector | Financials | Health |
52-Week High | $275.11 | $129.93 |
52-Week Low | $190.00 | $81.61 |
Enterprise Value | $74.96B | $20.04B |
Dividend Yield | 1.65% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
